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Abstract
Background: In prostate cancer (PCa), the common treatment involving androgen ablation alleviates the disease 
temporarily, but results in the recurrence of highly aggressive and androgen-independent metastatic cancer. Therefore, 
more effective therapeutic approaches are needed. It is known that aberrant epigenetics contributes to prostate 
malignancy. Unlike genetic changes, these epigenetic alterations are reversible, which makes them attractive targets in 
PCa therapy to impede cancer progression. As a histone methyltransferease, Ezh2 plays an essential role in epigenetic 
regulation. Since Ezh2 is overexpressed and acts as an oncogene in PCa, it has been proposed as a bona fide target of 
PCa therapy. MicroRNAs (miRNAs) regulate gene expression through modulating protein translation. Recently, the 
contribution of miRNAs in cancer development is increasingly appreciated. In this report, we present our study 
showing that microRNA-101 (miR-101) inhibits Ezh2 expression and differentially regulates prostate cancer cells. In 
addition, the expression of miR-101 alters upon androgen treatment and HIF-1α/HIF-1β induction.
Result: In our reporter assays, both miR-101 and miR-26a inhibit the expression of a reporter construct containing the 
3'-UTR of Ezh2. When ectopically expressed in PC-3, DU145 and LNCaP cells, miR-101 inhibits endogenous Ezh2 
expression in all three cell lines, while miR-26a only decreases Ezh2 in DU145. Ectopic miR-101 reduces the invasion 
ability of PC-3 cells, while restored Ezh2 expression rescues the invasiveness of PC-3 cells. Similarly, miR-101 also inhibits 
cell invasion and migration of DU145 and LNCaP cells, respectively. Interestingly, ectopic miR-101 exhibits differential 
effects on the proliferation of PC-3, DU-145 and LNCaP cells and also causes morphological changes of LNCaP cells. In 
addition, the expression of miR-101 is regulated by androgen receptor and HIF-1α/HIF-1β. While HIF-1α/HIF-1β 
induced by deferoxamine mesylate (DFO) decreases miR-101 levels, the overall effects of R-1881 on miR-101 expression 
are stimulatory.
Conclusions: This study indicates that miR-101 targets Ezh2 and decreases the invasiveness of PCa cells, suggesting 
that miR-101 introduction is a potential therapeutic strategy to combat PCa. MiR-101 differentially regulates prostate 
cell proliferation. Meanwhile, the expression of miR-101 is also modulated at different physiological conditions, such as 
androgen stimulation and HIF-1α/HIF-1β induction.
Background
Enhancer of zeste homolog 2 (Ezh2) is a member of the
polycomb group (PcG) protein family involved in sup-
pressing gene expression through remodeling chromatin
[1]. As a histone methyltransferase, Ezh2 catalyzes his-
tone H3 lysine 27 (H3-K27) trimethylation [2], which is a
hallmark of gene silencing [3]. Ezh2 is an important com-
ponent of the polycomb repressive complex 2 (PRC2) and
is required in maintaining gene silencing. The association
of Ezh2 with other PcG proteins is essential to its methyl-
transferase function, since the pharmacologic disruption
of PRC2 inhibits the methylation of H3-K27 [4]. Ezh2
needs to be recruited by DNA binding proteins, such as
YY1 and E2F, to associate with chromatin and exert its
function [5,6]. In addition, Ezh2 and its associated PcG
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proteins regulate various biological processes, including
X-chromosome inactivation [7], stem cell self-renewal
and exhaustion [8,9], skeletal muscle differentiation [10],
actin polymerization [11] and circadian clock function
[12].
Increasing evidence suggests an essential role of Ezh2
in cancers. Numerous studies indicate that Ezh2 overex-
pression is a common phenomenon in prostate cancer
(PCa) that is associated with a poor clinical outcome of
PCa patients [6,13-15]. Therefore, Ezh2 was proposed to
be a bona fide oncogene [13] and its increase can be used
as a marker of prostate tumors with aggressive and meta-
static potential. Several studies also suggested the pros-
pect of Ezh2 as a therapeutic target in PCa treatment.
Ezh2 knockdown by small interfering RNA (siRNA)
decreases prostate cell proliferation [13] and inhibits the
metastatic tumor growth of PC-3 cells in bone tissue [16].
On the other hand, Ezh2 promotes proliferation and inva-
sion of PCa cells [17] and ectopically expressed Ezh2 in
prostate cells enhances proliferation [18]. These studies
indicate a role of Ezh2 in aggressive PCa and suggest that
Ezh2 may be a therapeutic target of PCa treatment [18].
Taken together, Ezh2 plays an oncogenic role in PCa and
elucidating the mechanisms that regulate Ezh2 function
may provide fundamental therapeutic insight in treating
this cancer.
Previous studies demonstrate Ezh2 can be regulated at
the transcriptional or translational level. The tumor sup-
pressor p53 [19] and transcription factor E2F [6] can bind
to the promoter of the Ezh2 gene to inhibit or transacti-
vate its expression, respectively. In addition, Ezh2 under-
g o e s  p o s t - t r a n s l a t i o n a l  m o d i f i c a t i o n  b y  A k t ,  w h i c h
decreases its methyltransferase activity [20]. Recently,
increasing evidence indicates microRNAs (miRNAs) can
regulate gene expression at the post-transcriptional level.
Therefore, we wanted to study whether Ezh2 is also regu-
lated by miRNAs.
MicroRNAs are a group of small RNAs with 17-24
nucleotides that regulate gene expression through inter-
fering mRNA translation [21]. Ample evidence indicates
that miRNAs may regulate tumorigenesis by functioning
as either oncogenes or tumor suppressors [22]. Interest-
ingly, different cancers exhibit characteristic miRNA sig-
natures in miRNA expression profiling studies [23].
However, gaps still exist in understanding the precise
mechanisms of miRNA-mediated cancer development
and progression. Due to the importance of Ezh2 in PCa
progression and its potential as a therapeutic target in
PCa therapy, identifying miRNA(s) that regulates Ezh2
expression may lead to the development of novel thera-
peutic approaches in PCa treatment. A recent study indi-
cated that the genomic loss of miR-101 leads to Ezh2
overexpression in human cancer samples, suggesting the
physiological significance of miR-101-regulated Ezh2
function in PCa development [24]. In the current study,
we demonstrate that miR-101 negatively regulates Ezh2
expression in PCa cells and miR-101 expression is
affected by androgen stimulation and HIF-1α/HIF-1β
induction.
Materials and methods
Antibodies and Reagents
Antibodies against Ezh2 (4905), HIF-1β/ARNT (3718S),
Tri-Methyl-Histone H3-Lys 27 (H3K27m3, 9756), and
Lamin A/C (2032) were purchased from Cell Signaling
Technology (Danvers, MA). HIF-1α antibody was kindly
provided by Dr. Constantinos Koumenis (University of
Pennsylvania School of Medicine). Histone H3 (C-16, sc-
8654) and Androgen Receptor antibodies (N-20, sc-816)
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
MicroRNAs, siRNAs, DNA plasmids and transfection
All microRNA mimics (miR-101, miR-26a and a scramble
control) were synthesized by Dharmacon, Inc. (Chicago,
IL), with the following sequences: miR-101, UACAGUA-
CUGUGAUAACUGAA; miR-26a: UUCAAGUAAUCCA
GGAUAGGCU; and scramble control (miR-cont): UCA-
CAACCUCCUAGAAAGAGUAGA. The siRNAs for
control (GGG CCA TGG CAC GTA CGG CAA G) and
Ezh2 (GGT GAT CAC AGG ATA GGT ATT) were deliv-
ered by a lentiviral vector, pLU carrying anti-puromycin
cDNA [25].
To generate a reporter construct, we amplified a 493-
base pair (bp) DNA fragment consisting of the last 50 bps
of Ezh2 coding region and 443 bps of the 3'-UTR of Ezh2
mRNA from human genomic DNA (P/N: 5-0109,
Affymetrix, Inc.). This 3'-UTR region of Ezh2 containing
the predicted target sites of miR-101 and miR-26a was
then subcloned downstream of Gaussia luciferase (GLuc)
that is driven by a phosphoglycerate kinase (PGK) pro-
moter. We also constructed plasmids with mutated target
sites of these miRNAs. The recognition of the seed
sequence of a miRNA to the 7-8 nucleotides at the 3' end
of its target site is essential to miRNA-mediated transla-
tional inhibition. Thus, in the predicted target sites of
miR-101 and miR-26a in Ezh2 3'-UTR, we replaced these
nucleotides recognized by the seed sequences of these
two miRNAs with scrambled sequences, respectively. As
a result, we generated three control reporter plasmids
with the two miR-101 target sites mutated, either individ-
ually or combinatorially (45AGTACTGT66  to
ACCGCGGC, and/or 101GTACTGTA121 to CTGCAGAT,
mutated nucleotides are in bold), and one control
reporter plasmid with the mutated miR-26a target site
(236TACTTGAA257 to CTGCAGCT). To express Ezh2 in
PC-3 cells, Ezh2 cDNAs (generously provided by Dr. Sar-
torelli [10]) were individually subcloned into a LentiviralCao et al. Molecular Cancer 2010, 9:108
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vector, pSL4, which co-expresses the puromycin N-
acetyltransferase to render infected cells resistant to
puromycin.
Cell culture, transient transfection and Lentiviral 
production
PWR-1E, LNCaP, DU145 and PC-3 cell lines were
obtained from the American Type Culture Collection
(Manassas, VA). LNCaP, DU145 and PC-3 cells were
maintained in RPMI 1640 supplemented with 1% penicil-
lin/streptomycin and 10% fetal bovine serum. In andro-
gen starvation experiments, LNCaP cells were also
cultured in phenol red-free RPMI media containing 1%
charcoal-stripped FBS (Invitrogen), and treated with 0,
0.01, 0.1, and 10 nM R1881 (a synthetic non-aromatizable
androgen). PC-3 cells were also treated for 0 and 6 h by
100 μM deferoxamine mesylate (DFO, Sigma), dissolved
in RPMI culturing media. PWR-1E cells were maintained
in keratinocyte-SFM (Invitrogen). Lipofectamine 2000
(Invitrogen) was used in transient transfection of PC-3
cells based on the protocol provided by the manufacturer.
SiPort NeoFX lipofectamine (Ambion) was used in tran-
sient transfection of LNCaP based on the manufacturer's
protocol. The production of Lentivirus followed a previ-
ously reported protocol [26]. Briefly, 293T cells were
transfected with either an empty pSL4 vector, pSL4-Ezh2,
pLU-cont (control) siRNA, or pLU-Ezh2 siRNA, together
with three packaging plasmids (pMDLg/pRRE, pRSV-
RSE and pVSV-G) using a transfection protocol of cal-
cium phosphate-DNA precipitation. Medium containing
viral particles was collected 48 h after transfection. Lenti-
viruses in the medium were concentrated by ultracentrif-
ugation at 25,000 rpm, 4°C for 90 min and stored at -
80°C. To infect cells, concentrated Lentivirus was added
to the cells with the medium containing 8 μg/ml poly-
brene. The medium was replaced with normal culture
medium 6 h post viral addition.
Luciferase reporter assay
Each well of PC-3 cells cultured on a 12-well plate was
transfected with 50 ng of a reporter or mutated reporter
plasmid, miR-101 or miR-26a mimic (with a final concen-
tration of 100 nM in each well), 100 ng of plasmid
expressing secreted alkaline phosphatase (SEAP) driven
by a β-actin promoter and other expression plasmids if
needed. Aliquots of medium from the transfected wells
were collected 48 h posttransfection to measure
luciferase activity. Fifty μl of the medium (diluted if nec-
essary) was mixed with 100 μl of substrate solution con-
taining 0.5 μg/ml of coelenterazine (CTZ), 200 mM NaCl,
50 mM Tris·HCl and 0.01% Triton X-100, at pH 8.7. The
light emission was measured at a wavelength of 480 nm
and normalized with the SEAP expression [27].
Histone extraction
Cells were resuspended in Triton Extraction Buffer
(phosphate buffered saline, containing 0.5% Triton X-100,
2 mM phenylmethylsulfonyl fluoride, 0.02% NaN3), lysed
on ice with gentle shaking for 10 min, and centrifuged at
2,000 rpm for 10 min in 4°C. The cell pellet was washed
with the Triton Extraction Buffer and centrifuged as
above. To extract the histones, the cell pellet was resus-
pended in 0.2 N HCl and incubated overnight at 4°C with
gentle shaking. After centrifuging at 2,000 rpm for 10 min
in 4°C, the supernatant containing histone extract was
transferred to a new tube and analyzed by Western blot.
Clonogenic assay
PC-3 cells were transfected with control miRNA (miR-
cont) or miR-101 mimics using Lipofectamine 2000
(Invitrogen). Forty-eight hours post-transfection, cells
were plated at various densities (125, 250, 500, 1000 and
2000) in 6-cm cell culture dishes. After 7-10 days, the
cells were fixed with 10% formalin and stained with 0.1%
crystal violet. Colonies with 50-cells or greater were
counted on each dish.
Androgen Starvation and Bicalutamide treatment
LNCaP cells were seeded and cultured in complete
medium for 48 h. The medium was replaced by phenol
red-free RPMI media containing 1% charcoal-stripped
FBS (Invitrogen). Cells were allowed to adapt to this
androgen deprivation condition for an additional 24 h
before treating with 0, 0.01, 0.1, 1.0, and 10 nM R1881.
For the treatment of inhibiting androgen receptor,
LNCaP cells in the androgen deprivation condition were
pre-treated with 5 μM of bicalutamide (B9061, Sigma)
before R1881 addition.
WST-1 cell proliferation assay
LNCaP, DU-145 and PC-3 cells were assayed differently.
LNCaP cells were plated at a density of 6000 cells/well in
96-well plates and transfected with the control miRNA
(miR-cont) or miR-101 mimics using siPort NeoFX lipo-
fectamine (Ambion). At each time point, cell proliferation
in triplicates was measured using WST-1 (Roche) follow-
ing the manufacturer's protocol. DU-145 and PC-3 cells
were transfected with miR-cont or miR-101 mimics using
Lipofectamine 2000 (Invitrogen) in 6-well plates. Forty-
eight hours post-transfection, cells were seeded in tripli-
cate at a density of 2000 cells/ml in 96-well plates. Cell
proliferation at each time point was determined as
described above.
Real-Time RT-PCR analysis
Total RNA from cells was extracted using TRIzol reagent
(Invitrogen). Levels of mature forms of miR-101 or miR-
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Assays (Applied Biosystems), and data were normalized
to U6 expression (Applied Biosystems). To determine the
levels of Ezh2 mRNA in cells, 2 μg of RNA was incubated
with 0.5 μg/μl of oligo dT primer (Promega) at 70°C for 5
min. The following reverse transcriptase mix was then
added and incubated at 42°C for 1 h: 5 μl of 5× MMLV
buffer, 5 μl of 10 mM dNTP, 0.6 μl of RNasin, 1 μl of
MMLV reverse transcriptase, 13.4 μl of nuclease-free
water. Quantitative PCR analysis using Taqman Gene
Expression Assays was then performed for Ezh2 expres-
sion, and data were normalized to GAPDH expression
(Applied Biosystems). All analyses were performed using
the ABI7000 sequence detection system. The ΔΔCT
method [28] was used to calculate relative expression.
Matrigel invasion assay
One hundred μl of Matrigel (BD Biosciences, diluted to 1
mg/ml in serum free-cold cell culture media) was added
into an upper chamber of a 24-well transwell plate and
incubated at 37°C for 4 h until the Matrigel solidified.
Cells to be tested were starved in FBS-free medium for
18-24 h, then harvested by trypsinization and washed 3
times with medium containing 1% FBS and resuspended
in the same medium at a density of 1 × 106 cells/ml. The
polymerized Matrigel was gently washed with warmed
serum-free culture media. One hundred μl of the cell sus-
pension was added on top of the Matrigel, while 650 μl of
complete medium with 10% FBS was added to each bot-
tom chamber. The assembled chamber was incubated at
37°C in a cell culture incubator for 48 h. The medium in
the top and bottom chambers was carefully aspirated, fol-
lowed by washes with PBS. The cell invasion was quanti-
fied by counting the cells stained by crystal violet.
Migration Assay
LNCaP cells were transfected by miR-cont or miR-101
mimics. After 72 h, the cells were resuspended in RPMI
with 1% FBS at a density of 1 × 105 cells/ml. Five hundred
μl of the cell suspension was added to the upper chamber
(Becton Dickinson, 35-3097, 8 μm pore size), while 750 μl
of RPMI with 5% FBS was added to the lower chamber.
The chambers were incubated at 37°C in a cell culture
incubator for 24 h. Cell migration was quantified by
counting the cells stained by crystal violet.
Wound healing assay
LNCaP cells transfected by miR-cont or miR-101 mimics
were seeded in a 6 well plate and cultured for 72 h to
obtain 80% monolayer confluency. A wound was created
by scraping the cells using a plastic pipette tip, and the
medium was replaced with fresh medium. Images were
captured immediately (day 0) and every day for 5 days.
Cell migration was qualitatively assessed by the size of the
wounds at the end of the experiment.
Results
The 3'-UTR of Ezh2 mRNA contains conserved target sites of 
miR-101 and miR-26a
To identify miRNAs that potentially regulate Ezh2
expression, we analyzed the 3'-UTR sequence of human
Ezh2 using an algorithm available from the Sanger Insti-
tute (see [29] and http://microrna.sanger.ac.uk/) to pre-
dict potential miRNA target sites. We identified a
number of miRNA candidates that may regulate Ezh2
expression. We chose miR-101 and miR-26a for further
study, because these two miRNAs showed high binding
scores and their target sites on the 3'-UTR of Ezh2 are
conserved in a wide range of species, including human,
monkey, mouse, chicken and platypus. In addition, when
we used other algorithms of miRNA target prediction
[30-32] to analyze the Ezh2 sequence, these two miRNAs
also appeared in the lists as top candidates. Importantly,
two recent studies indicated that miR-26a targets Ezh2
[33,34] and other studies suggested these two miRNAs
are downregulated in cancers [35,36]. If we arbitrarily
designate the nucleotide right after the Ezh2 mRNA stop
codon as "1" and its downstream side as "+", two pre-
dicted targets sites of miR-101 are present at 45-66 and
101-121, while one miR-26a target site is at 236-257 (Fig.
1A). The alignment of miR-101 and miR-26a with their
putative target sequences on the human Ezh2 3'-UTR is
depicted in Fig. 1B.
Figure 1 Schematic diagrams of predicted targets of miR-101 and 
miR-26a in Ezh2 3'-UTR. A. Two predicted miR-101 target sites and 
one predicted miR-26a target site in the 3'-UTR of Ezh2. The first nucle-
otide right behind the stop codon of Ezh2 is arbitrarily designated as 
"1". B. Sequence alignments of miR-101 and miR-26a with their corre-
sponding potential target sites in the 3'-UTR of Ezh2. The seed se-
quences of the two miRNAs are bolded, and the matched or 
complementary nucleotides between the miRNAs and the Ezh2 3'-UTR 
are indicated. The positions of each predicted target on Ezh2 3'-UTR 
are labeled beneath the alignment.
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Expression of miR-101 and miR-26a in prostate cancer cell 
lines
Previous studies on miRNA profiles revealed decreased
levels of miR-101 and miR-26a in PCa [35,36]. To deter-
mine the correlation between the expression of these two
miRNAs and the malignancy of PCa cell lines, we used
Real-Time RT-PCR to study the expression of mature
form miR-101 and miR-26a in four different prostate cell
lines: PWR-1E, LNCaP, DU-145 and PC-3. While PWR-
1E is a non-tumorigenic prostate epithelial cell line [37],
the other three cell lines are tumorigenic and exhibited
increasing aggressiveness in an order of LNCaP, DU-145
and PC-3, as described in a previous study [38]. As shown
in Fig. 2, DU-145 and PC-3 cells showed markedly
decreased expression of miR-101, when compared to
PWR-1E cells (34% and 41% decrease, respectively, p <
0.05), while LNCaP cells exhibited a slight increase of
miR-101 expression (Fig. 2). Although the inverse corre-
lation between miR-26a expression and the aggressive-
ness of these four cell lines was only marginal, the
difference in the expression between PC-3 and PWR-1E
was still significant (30% decrease, p = 0.05).
Effects of ectopically expressed miR-101 and miR-26a on 
Ezh2 expression
To determine whether miR-101 and miR-26a target the
3'-UTR of Ezh2, we studied the effects of these two miR-
NAs on the reporters containing GLuc and the Ezh2 3'-
UTR. The intact (wt) reporter and its mutated versions
with replaced nucleotides at the binding sites of miR-101
or miR-26a are shown in Fig. 3A. When increasing
amounts (0, 50, 100 nM) of miR-101 and miR-26a were
transfected into PC-3 cells, the reporter construct with
intact Ezh2 3'-UTR showed decreased GLuc expression
(Fig. 3B). After we mutated the two miR-101 target sites
simultaneously, the generated reporter construct, m(45-
Figure 2 Analysis of miR-101 and miR-26a expression in prostate 
cancer cell lines. RT-PCR was conducted using RNAs extracted indi-
vidually from PWR-1E, LNCaP, DU-145 and PC-3 cells with a stem-loop 
primer specific to miR-101 or miR-26a. The generated cDNAs were sub-
jected to further analysis by Taqman Real-Time PCR using FAM-labeled 
miR-101 or miR-26a probes (Applied BioSystems). Each sample was an-
alyzed in triplicates. The data are presented as an average of two exper-
iments and normalized to the expression of the endogenous U6 RNA 
using the ΔΔCT method [28] as described in Materials and Methods. 
Student T-test was used to determine statistical significance and the 
asterisks indicate that the p values are not higher than 0.05.
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Figure 3 Analysis of miR-101 and miR-26a on Ezh2 3'-UTR in re-
porter assay, and endogenous Ezh2 expression. A. In wild type (wt) 
reporter, a 493-bp fragment containing the last 50 bps of Ezh2 coding 
region and the first 443 bps of Ezh2 3'-UTR embracing the predicted 
miR-101 and miR-26a target sites is subcloned downstream of GLuc 
driven by PGK promoter. The four reporter constructs contain muta-
tions in Ezh2 3'-UTR at miR-101 target sites: m(45-66), m(101-121) and 
m(45-66&101-121); and at miR-26a target site: m(236-257). B. Increas-
ing miR-101 and miR-26a (0, 50 and 100 nM, compensated with miR-
cont to 100 nM, if necessary) were cotransfected with wt reporter pre-
sented in "A" and the SEAP-expressing plasmid into PC-3 cells (tripli-
cated). GLuc activity was determined and normalized by SEAP activity 
(see Materials and Methods for details). C. One hundred nM of miR-
cont or miR-101 was cotransfected with 50 ng of the indicated reporter 
constructs and the SEAP-expressing plasmid. GLuc activity was mea-
sured and normalized as described above. D. The experiment was per-
formed as "C" using miR-26a and reporter plasmids as labeled. E. PC-3 
cells were transfected with miR-cont, miR-101, or miR-26a (120 nM). 
Ezh2 and β-actin expression was determined by Western blot. Relative 
Ezh2 levels normalized by β-actin are indicated. F. Ezh2 mRNA levels 
(normalized to GAPDH) in microRNA-transfected cells analyzed by 
Real-Time RT-PCR. The asterisk: p ≤ 0.05. G and H. GLuc activity mea-
surement (triplicated) and Western blot were performed as C, D and E 
in DU-145 (G) and LNCaP (H) cells.
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66&101-121), completely lost the response to the trans-
fected miR-101 (Fig. 3C). However, when we mutated the
two target sites individually, we observed that the GLuc
expression of the two reporter constructs, m(45-66) and
m(101-121), could be partially repressed by miR-101 (Fig.
3C). Interestingly, mutations in nucleotide (nt) 101-121 of
Ezh2 3'-UTR led to a more profound effect than that of nt
45-66, suggesting miR-101 interacts with these two sites
differentially. Similarly, a reporter construct with mutated
miR-26a target site, m(236-257), also lost the inhibition
to the reporter construct (Fig. 3D). The reporter assay
studies thus suggest that the presence of these miRNA
target sites in Ezh2 3'-UTR of the reporter construct is
necessary for the inhibition by miR-101 and miR-26a.
To determine the regulation of miR-101 and miR-26a
on endogenous Ezh2 expression, we individually trans-
fected the synthetic mimics of miR-101 and miR-26a in
PC-3 cells and studied the Ezh2 expression by Western
blot. As shown in Fig. 3E, ectopically expressed miR-101
decreased the expression of endogenous Ezh2 protein,
suggesting that miR-101 negatively regulates Ezh2 mRNA
translation. Interestingly, miR-26a did not show any
detectable inhibition to Ezh2 (Fig. 3E), although it effi-
ciently repressed the expression of the reporter construct
containing Ezh2 3'-UTR (Fig. 3B). In addition to the pro-
tein changes, we also detected a significant decrease of
Ezh2 mRNA in PC-3 cells transfected by miR-101 com-
pared to the cells transfected by miR-cont (30% ± 15, p <
0.05, Fig. 3F).
We also extended these studies in other prostate cell
lines. Reporter assays in DU145 and LNCaP cells showed
that miR-101 and miR-26a, but not miR-cont, signifi-
cantly inhibited the expression of the reporter construct
with Ezh2 3'-UTR. In DU145 cells, both miR-101 and
miR-26a decreased the expression of Ezh2 (Fig. 3G).
However, in LNCaP cells, miR-101, but not miR-26a,
downregulated Ezh2 expression (Fig. 3H).
Previous studies indicated that mutations or polymor-
phism in the 3'-UTR of a gene could abolish its respon-
siveness to the regulation of miRNAs [39,40]. Therefore,
we asked whether the inertness of the endogenous Ezh2
expression to ectopic miR-26a was due to the alteration
of the miR-26a target site at Ezh2 3'-UTR in PC-3 cells.
We amplified the region in the genomic DNA of PC-3
cells containing the miR-26a target site and analyzed the
PCR fragment by DNA sequencing. However, we did not
find any change in this predicted miR-26 target site when
compared with the human genomic DNA sequence in
NCBI (data not shown).
Effects of ectopic miR-101 on the proliferation, survivability 
and invasiveness of prostate cancer cells
Since our data indicate that miR-101 inhibited Ezh2
expression, we asked whether the miR-101-mediated
Ezh2 decrease may affect the histone methylation and the
PC-3 cell growth, survivability and invasiveness. Ezh2
regulates the expression of its target genes through medi-
ating histone H3-K27 tri-methylation [41]. Therefore, we
examined this modification in PC-3 cells transfected by
miR-101. As shown in Fig. 4A, ectopic expression of miR-
101 led to the concomitant decrease of both Ezh2 and
histone H3-K27 methylation, while the total histone H3
remained unchanged. Using these cells to determine the
effect of miR-101 on cell growth, we did not detect signif-
icant change in cell proliferation (Fig. 4B, top panel).
Meanwhile, the clonogenic assay showed that miR-101
did not change the colony formation of PC-3 cells, which
suggested unchanged cell survivability (Fig. 4B, middle
panel). We asked whether the modest Ezh2 decrease by
miR-101 in PC-3 cells is insufficient to cause any change
in cell growth. Therefore, we infected PC-3 cells by lenti-
virus carrying Ezh2 siRNA that could knock down the
Figure 4 Effects of ectopically expressed miR-101 on the growth, 
survivability and invasiveness of PC-3 cells. A. Effect of ectopic miR-
101 on histone H3-K27 methylation. PC-3 cells were transfected with 
miR-cont or miR-101 (120 nM). Aliquots of transfected cells were ana-
lyzed by Western blots using the indicated antibodies. Relative protein 
expression is indicated at the bottom of each image. B. Effects of Ezh2 
downregulation on proliferation and colony formation of PC-3 cells. In 
the top and middle panels, aliquots of transfected PC-3 cells in "A" 
were studied by WST-1 proliferation assay (top) and clonogenic assay 
(middle). In the bottom panel, PC-3 cells infected by lentivirus carrying 
the control and Ezh2 siRNAs were tested by WST-1 assay and Ezh2 
knockdown tested by Western blot was indicated. C. Effects of ectopic 
miR-101 on the invasiveness of PC-3 cells using aliquots of transfected 
PC-3 cells in A. The asterisk indicates p < 0.05 and representative imag-
es are presented. D and E. Effects of restored Ezh2 expression on miR-
101 transfected PC-3 cells. In D, PC-3 cells were either infected with 
lentivirus generated from pSL4 vector or pSL4-Ezh2 as indicated. At 48 
h post infection, cells were transfected with 120 nM of miR-cont or 
miR-101 as labeled. After another 48 h, cells were analyzed by Western 
blots using the indicated antibodies. In E, aliquots of the infected/
transfected PC-3 cells with the corresponding sample numbers (1, 2 
and 3) in D were studied by invasion assay. Percent invasion is shown 
with "*" indicating p < 0.05 and representative images.
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endogenous Ezh2 by over 90%. In the cell proliferation
study, these Ezh2-siRNA transduced PC-3 cells exhibited
marked defects in cell proliferation compared to the cells
expressing a control siRNA (Fig. 4B, bottom panel).
We further studied the invasive capability of these cells
using the Matrigel invasion assay. As shown in Fig. 4C,
the PC-3 cells expressing ectopic miR-101 exhibited sig-
nificantly decreased ability of penetration (46% ± 12, p <
0.05) compared to the cells expressing miR-cont, suggest-
ing that ectopic miR-101 inhibited the invasiveness of
PCa cells. Since the correlation between Ezh2 inhibition
and attenuated PCa progression has been well-docu-
mented [13,17], we asked whether the Ezh2 decrease by
miR-101 is the primary cause of the compromised inva-
siveness of miR-101 transfected cells. We infected the
miR-101 transfected PC-3 cells with lentivirus expressing
Ezh2, which could restore the Ezh2 expression to a com-
parable level (90%) of the endogenous Ezh2 (Fig. 4D). In
the invasion assay, the PC-3 cells with restored Ezh2
expression exhibited similar penetration ability to the
miR-cont transfected cells (92% ± 2.6, p < 0.05, compare
columns 3 and 1 of Fig. 4E), suggesting that miR-101
attenuates the invasiveness of PC-3 cells primarily
through downregulating Ezh2 expression.
We asked if the phenomenon of PC-3 cells with ectopi-
cally expressed miR-101 could be extended to other pros-
tate cell lines. Therefore, we studied the effects of ectopic
miR-101 on DU-145 and LNCaP cells. In DU-145 cells,
we observed that miR-101 inhibited both cell prolifera-
tion and invasion (Fig. 5A and 5B). This result is consis-
tent with a recent study demonstrated by Chinnaiyan
group [24]. Both PC-3 and DU-145 are aggressive and
androgen receptor (AR) negative PCa cell lines. We fur-
ther studied the effects of miR-101 on LNCaP cells that
have relatively low aggressiveness and are AR positive.
We first observed that LNCaP cells expressing ectopic
miR-101 exhibited a morphological change with exten-
sion of the cytoplasmic portion and rounding of the cell
body, compared to the typical fusiform morphology of
LNCaP cells expressing the miR-cont (Fig. 5C). This
might not be caused by neuroendocrine differentiation,
since several markers for neuroendocrine cells did not
show significant changes (data not shown). It is notewor-
thy that these morphological changes were not observed
in PC-3 and DU-145 cells transfected by miR-101 (data
not shown). Unexpectedly, LNCaP cells expressing ecto-
pic miR-101 displayed increased cell proliferation com-
pared to miR-cont transfected cells, which is opposite to
the effects of miR-101 on DU-145 cells (Fig. 5D). This
phenomenon is reproducible in multiple independent
experiments. Since these morphological changes of
LNCaP cells may alter their cytoskeletal structure and
affect cell migration, we assessed the migration of these
cells using wound healing and Boyden Chamber cell
migration assays. In both studies, LNCaP cells trans-
fected by miR-101 exhibited decreased migrating rates
than the cells with miR-cont (Fig. 5E and 5F).
Effects of HIF-1α/HIF-1β and androgen receptor on the 
expression of miR-101
L i k e  p r o t e i n - c o d i n g  m R N A s ,  m i R N A s  a r e  a l s o  t r a n -
scribed from their genes in genomic DNA. Therefore, the
expression of each miRNA is driven by a promoter and
regulated by transcription factors [42]. To investigate the
mechanism regulating miR-101 expression, we analyzed
the upstream region of its coding sequence in the human
genome using an algorithm that predicts transcription
factor binding elements on DNA [43]. We identified a
number of proteins that have the potential to regulate
miR-101 expression and focused on the regulatory pro-
teins with both high binding probability scores and previ-
ously reported roles in cancers. Two of these proteins are
hypoxia inducible factor-1β (HIF-1β) and AR, whose
binding elements are located upstream of the miR-101
Figure 5 Effects of miR-101 on DU-145 and LNCaP cells. A and B. 
Effects of ectopic miR-101 on the proliferation and invasiveness of DU-
145 cells. DU-145 cells were transfected by 120 nM of miR-cont or miR-
101 mimics and cells were collected at 72 h post-transfection. Aliquots 
of the cells of each treatment were studied in triplicates by (A) WST-1 
cell proliferation assay and (B) Matrigel invasion assay. Western blot 
analyses of these transfected cells are shown as an insert of "A" and 
representative images of invasion assay are also shown in "B" (right 
panel). C, and D. Effects of ectopic miR-101 on the morphology and 
proliferation of LNCaP cells. In C, the LNCaP cells at 72 h post transfec-
tion were imaged under microscope (20×). The black arrow heads in-
dicate the rounding of the cell body, while the white arrow heads 
point the extensions of cell cytoplasmic portion. In D, the LNCaP cells 
were seeded in triplicate at a density of 6000 cells/well in 96-well plates 
and transfected with 120 nM of miR-cont or miR-101 mimics. Cell pro-
liferation was studied by WST-1 reagent. E. Wound healing assay of LN-
CaP cells transfected with miRNA mimics (120 nM). Images were 
captured at the time points as indicated. F. Boyden chamber migration 
assay of LNCaP cells transfected with miRNA mimics (120 nM). The cell 
numbers were quantified after crystal violet staining with represented 
images shown below.
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precursor at -95 to-79 and -1694 to -1676, respectively
(Fig. 6A).
HIF-1β interacts with HIF-1α to form a heterodimer
that regulates the transcription of hypoxia-responsive
genes in PCa angiogenesis and progression [44]. HIF-1α
expression can be stimulated by various signaling path-
ways. Therefore, to determine the effect of HIF-1β on
miR-101, we treated PC-3 cells with 100 μM of deferox-
amine mesylate (DFO), an iron chelator that induces HIF-
1α expression [45]. As shown in the left panel of Fig. 6B,
at 6 h post DFO treatment, PC-3 cells exhibited an
increase of Ezh2 expression with concomitant increases
of both HIF-1α and HIF-1β compared to the mock-
treated cells. Importantly, the miR-101 levels in the DFO-
treated PC-3 cells exhibited a significant decrease to 72%
(p < 0.05) compared to the control (right panel, Fig. 6B),
suggesting that the HIF-1α/HIF-1β heterodimer down-
regulates miR-101.
To test how AR regulates miR-101 expression, we
treated androgen dependent LNCaP cells with 10 nM of
R1881 and observed a significant increase of miR-101
(50% ± 20, Fig. 6C). To determine if this phenomenon was
due to the AR's function, we pretreated LNCaP cells with
5 μM of bicalutamide, an antagonist of AR. As a result of
inhibiting the functional AR, we abolished the miR-101
induction caused by R1881 (Fig. 6C). Consistently, with
the induction of miR-101 by R1881, we observed concur-
rent Ezh2 decrease, which was partially restored by
bicalutamide treatment (Fig. 6D).
AR plays an essential role in the development of normal
prostate gland and the growth of PCa [46]. R1881 can
both induce the differentiation and affect the prolifera-
tion of LNCaP cells [47,48]. Especially, different concen-
trations of R1881 exert differential effects on the growth
of LNCaP cells [47]. Therefore, we studied miR-101 and
Ezh2 expression of LNCaP cells cultured in medium with
1% charcoal-stripped serum and 0, 0.01, 0.1, 1 or 10 nM
of R1881. Cells with these treatments were counted at
days 0 and 6 to evaluate their growth, while the miR-101
levels and protein expression were determined by Real-
Time PCR and Western blot, respectively. As shown in
Fig. 6E, LNCaP cells exhibited biphasic growth rates in
response to R1881. While 0.01 nM of R1881 stimulated
the growth of LNCaP cells, further increases of R1881
adversely affected the cell proliferation. This observation
is consistent with a previous study of R1881's effects on
LNCaP cells [47]. Meanwhile, the treatments of 0.01, 0.1
and 10 nM of R1881 significantly increased miR-101
expression in LNCaP cells (by 40% ± 14, 50% ± 29 and
50% ± 26, respectively. p < 0.05, n = 4, Fig. 6F). However,
for unknown reasons, 1 nM of R1881 did not significantly
change miR-101 levels (p = 0.07, n = 4), which was repro-
ducible in 4 individual studies. The effect of R1881 was
validated by the marked PSA induction in response to
increasing R1881 concentrations, consistent with previ-
ous studies [47,48]. Meanwhile AR levels were also ele-
vated (Fig. 6G). In addition, the overall Ezh2 expression
negatively correlated to the AR increases and miR-101
induction, except at the 1.0 nM of R1881 (Fig. 6F and 6G).
Discussion
Prostate tumorigenesis is accompanied by deregulated
gene expression. It has been well established that aber-
rant DNA methylation and histone modifications con-
tribute to these processes. Recently, changes of miRNA
profile in cancer cells and their roles in tumorigenesis
have been increasingly appreciated. Since the major bio-
logical function of miRNAs is mediating gene expression,
we investigated how essential genes in prostate tumori-
genesis are regulated by different miRNAs, and whether
the miRNA-mediated gene expression is important in
PCa development. Multiple studies indicated that Ezh2 is
potentially a prognostic marker and therapeutic target of
PCa [15,18,49]. Therefore, our initial study investigated
Figure 6 Effects of HIF-1β and AR on miR-101 expression. A. Sche-
matic diagram of HIF-1β and AR binding elements upstream of miR-
101 coding region. B. Protein and miR-101 expression of DFO-treated 
PC-3 cells. Nuclear proteins of PC-3 cells treated with 100 μM DFO or 
mock were analyzed by Western blot (left panel) and Real-Time RT-PCR 
(right panel, average of two individual experiments with triplicated 
samples). C and D. LNCaP cells were treated by R1881 and bicalut-
amide as indicated and analyzed by (C) Real-Time RT-PCR for miR-101 
(average of three individual experiments) and (D) Western blot for 
Ezh2. E, F and G. Effects of R1881 on cell growth, miR-101 levels and 
gene expression in LNCaP cells. In E, cells were seeded at 1 × 105 cells/
well on 6-well plates in phenol red-free RPMI medium with 1% char-
coal-stripped FBS, followed by treatment of 0, 0.01, 0.1, 1.0, and 10 nM 
of R1881. At days 0 and 6, cells in triplicates were counted. Data are the 
averages of three or more individual experiments. In F, miR-101 levels 
in the extracted RNA at day 6 were determined by Real-Time RT-PCR 
with each sample analyzed in triplicate. Data are the average of four in-
dependent experiments. Student t-test was used to determine statisti-
cal significance (* indicates p < 0.05). In G, whole cell lysates at day 6 of 
the treatment were analyzed by Western blot using the antibodies la-
beled on the left.
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whether Ezh2 expression is regulated by miRNAs in pros-
tate tumorigenesis.
In this report, we demonstrated that the 3'-UTR of
Ezh2 contains the target sites of both miR-101 and miR-
26a and these sites are conserved among different spe-
cies. However, while ectopic expression of miR-101
decreased the endogenous Ezh2 in all three tested cell
lines, miR-26a only inhibited Ezh2 in DU-145 cells, but
not in PC-3 and LNCaP cells. The mechanism underlying
this observation is still unclear and advanced understand-
ing of the dynamic regulation of miRNAs may provide an
explanation of this phenomenon. Currently, several algo-
rithms are available to predict potential miRNA target
sites in a given mRNA sequence. Most of them employ a
scoring system that identifies highly complementary sites
using dynamic programming alignment and rewards
complementarity at the 5' end of the microRNA. How-
ever, these algorithms cannot predict whether a potential
target site is blocked by a secondary structure or RNA
binding protein(s), which makes it inaccessible [50]. A
recent report also indicates that single nucleotide poly-
morphisms inside microRNA target sites affect miRNA-
mediated gene inhibition and consequently influence
tumor susceptibility [40]. Therefore, the presence of a
miRNA target site in a mRNA does not assure that the
gene is regulated by this miRNA. On the other hand, a
handful of evidence suggests that genes regulated by cer-
tain miRNAs may not contain canonical target sites pre-
dicted by most algorithms [51-53]. Since our DNA
sequencing analysis did not detect any mutation at the
potential miR-26a target site in Ezh2 3'-UTR of PC-3
cells, we predict that lack of inhibition of miR-26a to the
endogenous Ezh2 expression may be due to the interfer-
ence of RNA binding proteins in PC-3 and LNCaP cells.
When the 493-bp DNA fragment containing 443-bp of
Ezh2 3'-UTR was subcloned into the reporter construct,
these potential RNA binding proteins that interfere with
the miRNA binding may have been saturated due to the
robust expression of the reporter plasmid. This may
explain the responsiveness of the reporter construct to
the ectopic miR-26a in all three cell lines. Since the com-
position of the cellular proteins and microenvironment
can be cell type specific, the response of endogenous
Ezh2 expression to miR-26a may also change. Therefore,
miR-26a could downregulate Ezh2 in DU145 cells, but
not in PC-3 and LNCaP cells (Fig. 3G). In addition, miR-
26a was also reported to negatively regulate Ezh2 expres-
sion in myoblasts and lymphoma cells [33,34].
MicroRNAs have been implicated in fine tuning the
expression of target genes to physiologically relevant lev-
els [54,55]. Therefore, consistent with previous reports
on miRNAs' modulation of other gene expression, ectopi-
cally expressed miR-101 did not dramatically dampen the
e x p r e s s i o n  o f  e n d o g e n o u s  E z h 2 ,  a l t h o u g h  i t  e x h i b i t e d
much more pronounced inhibition to the luciferase
reporter construct. Certainly, miR-101 must not be the
only regulator of Ezh2 expression and it very likely collab-
orates with other miRNAs or transcription factors to
adjust Ezh2 expression under different physiological con-
ditions. However, it is reasonable to predict that down-
regulated miR-101 contributes to the increased
expression of Ezh2 observed in PCa cells relative to the
levels seen in normal prostate cells.
We observed ectopic miR-101 inhibited Ezh2 expres-
sion and led to markedly decreased invasiveness of all
three tested cell lines. Importantly, our results of the neg-
ative regulation of Ezh2 by miR-101 are consistent with a
recent report from the Chinnaiyan group showing that
the genomic loss of miR-101 causes Ezh2 upregulation in
PCa [24]. At least in PC-3 cells, this phenomenon was
due to the concomitantly reduced Ezh2 expression, since
ectopically expressed Ezh2 restored the invasiveness (Fig.
4E). Consistently, we also observed the inhibitory effects
of miR-101 on the invasiveness of DU145 cells and
migrating ability of LNCaP cells (Fig. 5B and 5F). How-
ever, miR-101 exhibited differential effects on the prolif-
eration of PC-3, DU-145 and LNCaP cells (Fig. 4B, 5A
and 5D). While ectopic miR-101 caused growth defects of
DU-145 cells and did not affect that of PC-3 cells, it sur-
prisingly promoted LNCaP cell proliferation with con-
current morphological changes that were not observed in
PC-3 and DU-145 cells. These results indicate that the
ectopic miR-101 has differential effects in different pros-
tate cell lines. The mechanisms underlying these pheno-
typic discrepancies need further investigation. It is also
noteworthy that PC-3 cells are more aggressive than DU-
145 and LNCaP cells, and PC-3 and DU145 are both
androgen independent and AR negative. LNCaP cells are
androgen dependent and have the lowest malignancy
among these three cell lines. Thus, the effects of miR-101
introduction on cell proliferation may rely on the aggres-
siveness and AR status of the cells.
LNCaP cells with ectopic miR-101 exhibited a morpho-
logical change. In a time-lapse video microscopy study,
we observed that these cells formed cytoplasmic exten-
sions, reminiscent of filopodia, which was not shown in
the cells expressing miR-cont (data not shown). When we
further investigated whether this morphological change
affected cell migration, we detected the decreased
migrating rates in miR-101 transfected LNCaP cells com-
pared to the cells with miR-cont (Fig. 5E-F). It is unclear
whether Ezh2 regulates these alterations. We predict that
other miR-101 regulated genes involved in cell migration
may play a role in this morphological change of LNCaP
cells.
We did not detect any significant difference of Ezh2
mRNA levels among PWR-1E, LNCaP, DU-145 and PC-3
cell lines, which is consistent with a previous study [13].Cao et al. Molecular Cancer 2010, 9:108
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These results suggest that at least in these cell lines Ezh2
overexpression in PCa is likely regulated at posttranscrip-
tional levels, but not at transcription.
The effects of HIF-1β and AR on miR-101 indicate that
the expression of miRNAs respond to the physiological
and environmental changes. The DFO-induced expres-
sion of HIF-1α and HIF-1β led to decreased miR-101
expression, suggesting that miR-101 is a component in
hypoxia-regulated signaling pathways. We also observed
the upregulation of miR-101 in LNCaP cells treated by 10
nM of R1881, which was attenuated by an AR antagonist,
b i c a l u t a m i d e .  I t  i s  n o t e w o r t h y  t h a t  b i c a l u t a m i d e  a l o n e
did not significantly decrease miR-101 levels (Fig. 6C),
suggesting that without androgen stimulation AR does
not have any detectable effect on miR-101 expression.
However, in our further studies, although R1881 at 0.01
and 0.1 nM showed similar effects to that at 10 nM, the 1
nM of R1881 did not show any stimulation to miR-101
expression in multiple experiments (Fig. 6F). Meanwhile,
at 0.01 nM of R1881 with increased miR-101 expression,
cell proliferation was unexpectedly enhanced (Fig. 6E and
6F). The mechanisms to interpret these unexpected
changes are unclear. We predict that differential activa-
tion of androgen-stimulated signaling pathways may con-
tribute to them. Especially at 1 nM of R1881, certain
proteins or pathways that need to be identified may have
been altered, which causes the bypass of AR's regulation
to miR-101 and consequently leads to the observation
inconsistent with these at other R1881 levels. Multiple
previous studies also demonstrated the differential effects
of androgen on prostate cell proliferation [47,48].
We also noticed that at certain concentrations (0.1 and
1.0 nM) of R1881, the expression levels of miR-101 and
Ezh2 (Fig. 6F and 6G) did not show a correlation as we
observed in Fig. 6C. We predict that other R1881/andro-
gen receptor-regulated pathways may play a role in medi-
ating Ezh2 expression at these conditions.
Overall, the regulation of HIF-1α/HIF-1β and androgen
receptor suggests a role of miR-101 in tumor progression
and normal prostate development. Further investigation
is needed to delineate the mechanisms underlying the
altered expression of miR-101 during prostate cancer
hypoxia and prostate cell differentiation.
Conclusions
Current therapeutic treatment of PCa frequently leads to
reoccurred cancers with more aggressive and refractory
characteristics. Hence, it is crucial to identify new thera-
peutic targets and develop more effective approaches to
treat this disease. Ezh2 regulates histone methylation and
contributes to the aberrant epigenetics in PCa. Impor-
tantly, Ezh2 overexpression correlates with the pathologi-
cal degrees and tumor progression of this cancer,
suggesting its potential as a therapeutic target. MiR-101
negatively regulates Ezh2 expression and concurrently
attenuates the invasion ability of prostate cancer cells,
which can be rescued by ectopically expressed Ezh2. This
implicates that the inhibition of Ezh2 by miR-101 is a pro-
spective approach to be used as a new strategy in PCa
therapy. Moreover, the levels of miR-101 fluctuate upon
the androgen treatment and HIF-1α/HIF-1β induction,
suggesting it is differentially regulated at different physio-
logical conditions. Overall, our study indicates that miR-
101 plays a regulatory role in prostate tumorigenesis and
restoring miR-101 levels may be an effective approach for
PCa treatment.
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